Tafamidis vs placebo
Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 1.16 [0.37, 3.62]1 study · 128 participantsVery low